Gudiol, CarlotaRoyo-Cebrecos, CristinaAbdala, EdsonAkova, MuratAlvarez, RocioMaestro-de la Calle, GuillermoCano, AngelaCervera, CarlosClemente, Wanessa T.Martin-Davila, PilarFreifeld, AlisonGomez, LuciaGottlieb, ThomasGurgui, MerceHerrera, FabianManzur, AdrianaMaschmeyer, GeorgMeije, YolandaMontejo, MiguelPeghin, MaddalenaRodriguez-Bano, JesusRuiz-Camps, IsabelSukiennik, Teresa C.Tebe, CristianCarratala, Jordi2023-02-122023-02-122017-04-27Gudiol C, Royo-Cebrecos C, Abdala E, Akova M, Álvarez R, Maestro-de la Calle G, et al. Efficacy of β-Lactam/β-Lactamase Inhibitor Combinations for the Treatment of Bloodstream Infection Due to Extended-Spectrum-β-Lactamase-Producing Enterobacteriaceae in Hematological Patients with Neutropenia. Antimicrob Agents Chemother. 2017 Jul 25;61(8):e00164-170066-4804http://hdl.handle.net/10668/18998beta-Lactam/beta-lactamase inhibitors (BLBLIs) were compared to carbapenems in two cohorts of hematological neutropenic patients with extended-spectrum beta-lactamase (ESBL) bloodstream infection (BSI): the empirical therapy cohort (174 patients) and the definitive therapy cohort (251 patients). The 30-day case fatality rates and other secondary outcomes were similar in the two therapy groups of the two cohorts and also in the propensity-matched cohorts. BLBLIs might be carbapenem-sparing alternatives for the treatment of BSI due to ESBLs in these patients.enESBLsBloodstream infectionNeutropeniaBeta-lactam/beta-lactamase inhibitorsMortalityEscherichia-coliKlebsiella-pneumoniaePiperacillin-tazobactamRisk-factorsBacteremiaCarbapenemsTherapyMortalityOutcomesCancerresearch articleopen accessCarbapenémicosNeoplasiasPiperacilinaRiesgoTazobactamTerapéuticaMortalidad10.1128/AAC.00164-171098-6596https://europepmc.org/articles/pmc5527609?pdf=render406259400008